Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SRRA Sierra Oncology (SRRA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Sierra Oncology Stock (NASDAQ:SRRA) 30 days 90 days 365 days Advanced Chart Ad Weiss RatingsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get Sierra Oncology alerts:Sign Up Key Stats Today's Range$54.99▼$54.9950-Day Range$54.73▼$54.9952-Week Range$14.91▼$55.19VolumeN/AAverage Volume931,731 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.Read More… Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (Ad)Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Receive SRRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address SRRA Stock News HeadlinesSierra Space eyes IPO market as it braces for a 'profound industrial revolution' in spaceApril 11, 2024 | msn.comSierra Oncology Inc.February 21, 2024 | thestreet.comNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …November 14, 2024 | Weiss Ratings (Ad)Sierra Coupon for OctoberNovember 9, 2023 | time.comFDA approves GSK's unique myelofibrosis treatment OjjaaraSeptember 18, 2023 | msn.comPleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology DealSeptember 18, 2023 | msn.comFDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemiaSeptember 18, 2023 | msn.comAnalyst calls of the week: Palo Alto upped, Carnival earnings preview and moreJune 16, 2023 | proactiveinvestors.comSee More Headlines SRRA Stock Analysis - Frequently Asked Questions How were Sierra Oncology's earnings last quarter? Sierra Oncology, Inc. (NASDAQ:SRRA) issued its quarterly earnings data on Friday, November, 5th. The biotechnology company reported ($2.10) EPS for the quarter, missing analysts' consensus estimates of ($1.78) by $0.32. What other stocks do shareholders of Sierra Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sierra Oncology investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), T2 Biosystems (TTOO), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), Trevena (TRVN) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/05/2021Today11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SRRA Previous SymbolNASDAQ:DNAI CUSIPN/A CIK1290149 Webwww.sierraoncology.com Phone(604) 558-6536FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.88% Return on Assets-100.01% Debt Debt-to-Equity Ratio0.02 Current Ratio21.27 Quick Ratio21.27 Sales & Book Value Annual Sales$300,000.00 Price / Sales4,476.00 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book8.93Miscellaneous Outstanding Shares24,419,000Free Float13,650,000Market Cap$1.34 billion OptionableOptionable Beta0.03 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:SRRA) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersWhat are you hiding Elon?? (Tesla’s secret 69% dividend)Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sierra Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sierra Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
